Endo in a Bite

Sumbul Beg, MD
  • 0,0 (0)
  • Medycyna
  • Uakt. codziennie

This podcast from EZ Endo Prep delivers concise, high yield endocrinology content to help you study smarter and practice with confidence. Each episode breaks down complex topics into manageable pieces, making it ideal for endocrinology fellows and practicing endocrinologists. Whether you're preparing for boards or staying sharp in clinic, Dr. Sumbul Beg, MD brings exam ready pearls and real world relevance straight to your ears.

  1. 4 dni temu

    The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Glucose Centric Management (Episode 10)

    In this episode, we review the 2026 Consensus Statement algorithm for glucose centric management in adults with type 2 diabetes. Topics include identifying patients appropriate for a glucose centric approach, metformin as foundational therapy, individualized medication selection based on weight, hypoglycemia risk, cost and access, early combination therapy, management of severe hyperglycemia, appropriate insulin initiation, avoiding inappropriate incretin combinations, and practical strategies for treatment intensification and reducing therapeutic inertia.

  2. 27 lip

    The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Metabolic Dysfunction Associated Steatotic Liver Disease (Episode 9)

    In this episode, we review the 2026 Consensus Statement algorithm for metabolic dysfunction associated steatotic liver disease (MASLD) management in adults with type 2 diabetes. Topics include the epidemiology and diagnosis of MASLD, progression to metabolic dysfunction associated steatohepatitis (MASH), lifestyle interventions and weight loss goals, the role of resmetirom, GLP-1 receptor agonists, tirzepatide, pioglitazone, and SGLT2 inhibitors, and practical evidence based strategies to improve liver health and reduce cardiovascular, renal, and hepatic complications.

  3. 20 lip

    The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Stroke and Transient Ischemic Attack (Episode 8)

    In this episode, we review the 2026 Consensus Statement algorithm for stroke and transient ischemic attack management in adults with type 2 diabetes. Topics include stroke risk in type 2 diabetes, evidence supporting GLP-1 receptor agonists for stroke risk reduction, and cardiovascular outcomes with dulaglutide, liraglutide, injectable semaglutide, tirzepatide, and pioglitazone. We also discuss secondary stroke prevention in adults with insulin resistance, prediabetes, or type 2 diabetes, lower dose pioglitazone to improve tolerability, the limited role of SGLT2 inhibitors in stroke prevention, and practical evidence based strategies for reducing stroke risk in clinical practice.

  4. 13 lip

    The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Atherosclerotic Cardiovascular Disease Management (Episode 7)

    In this episode, we review the 2026 Consensus Statement ASCVD management algorithm for adults with Type 2 Diabetes. Topics include cardiovascular risk reduction, major adverse cardiovascular events, and the evidence supporting GLP-1 receptor agonists and SGLT2 inhibitors for cardiovascular protection. We discuss semaglutide, liraglutide, dulaglutide, tirzepatide, and the cardiovascular safety of DPP-4 inhibitors. We also review treatment recommendations for adults with established ASCVD or high cardiovascular risk, the role of SGLT2 inhibitors in heart failure and chronic kidney disease, and practical evidence based strategies for cardiovascular risk reduction in clinical practice.

  5. 6 lip

    The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Chronic Kidney Disease Management (Episode 6)

    In this episode, we review the 2026 Consensus Statement algorithm for the management of chronic kidney disease in adults with Type 2 Diabetes. Topics include SGLT2 inhibitors as foundational renoprotective therapy, evidence based pharmacologic management of diabetic kidney disease, and strategies to reduce CKD progression, kidney failure, and cardiovascular events. We discuss canagliflozin, dapagliflozin, empagliflozin, finerenone, and GLP-1 receptor agonists, including semaglutide and the FLOW trial, along with eGFR initiation thresholds, albuminuria guided treatment, and combination therapy for persistent residual kidney risk. We also review therapeutic sequencing, cardiorenal protection, monitoring of eGFR, albuminuria, and serum potassium, board relevant treatment recommendations, pivotal clinical trials, and high yield facts for ABIM certification, recertification, LKA, and clinical practice.

  6. 29 cze

    The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Heart Failure Management (Episode 5)

    In this episode, we review the 2026 Consensus Statement algorithm for heart failure management in adults with Type 2 Diabetes. Topics include the foundational role of SGLT2 inhibitors, heart failure with reduced and preserved ejection fraction, and evidence based pharmacologic therapy. We discuss dapagliflozin, empagliflozin, sotagliflozin, GLP-1 receptor agonists, and the role of semaglutide, tirzepatide, and liraglutide in different heart failure phenotypes. We also review medications that may worsen heart failure, including thiazolidinediones and selected DPP-4 inhibitors, therapeutic priorities for reducing hospitalization and cardiovascular mortality, and board relevant treatment recommendations, key clinical trials, and high yield facts to remember for exam preparation and clinical practice.

  7. 22 cze

    The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Hypertension Management (Episode 4)

    In this episode, we review the 2026 Consensus Statement hypertension algorithm for adults with Type 2 Diabetes. Topics include blood pressure targets, screening for secondary causes of hypertension, proper blood pressure measurement techniques, lifestyle interventions, and evidence based pharmacologic therapy. We discuss ACE inhibitors, ARBs, thiazide diuretics, calcium channel blockers, resistant hypertension management, mineralocorticoid receptor antagonists including spironolactone and finerenone, and the role of GLP-1 receptor agonists and SGLT2 inhibitors in blood pressure reduction. We also highlight board relevant treatment thresholds, cardiovascular risk reduction strategies, and key numbers to remember for exam preparation and clinical practice.

  8. 15 cze

    The 2026 Consensus Statement on the Algorithm for Management of Adults with Type 2 Diabetes: Lipid Management (Episode 3)

    In this episode, we review the 2026 Consensus Statement on Lipid Management in Adults with Type 2 Diabetes. Topics include ASCVD risk assessment, LDL-C treatment targets, statin therapy, coronary artery calcium scoring, nonstatin lipid lowering therapies, triglyceride management, and key differences between ACC/AHA and AACE recommendations. We also discuss practical treatment strategies and board relevant pearls for cardiovascular risk reduction.

Wyświetl wszystko (58)

O programie

This podcast from EZ Endo Prep delivers concise, high yield endocrinology content to help you study smarter and practice with confidence. Each episode breaks down complex topics into manageable pieces, making it ideal for endocrinology fellows and practicing endocrinologists. Whether you're preparing for boards or staying sharp in clinic, Dr. Sumbul Beg, MD brings exam ready pearls and real world relevance straight to your ears.

Informacje

  • Twórca
    Sumbul Beg, MD
  • Lata aktywności
    2025 - 2026
  • Odcinki
    58
  • Klasyfikacja
    Dla wszystkich
  • Prawa autorskie
    © Sumbul Beg, MD
  • Witryna programu
    Endo in a Bite

Możesz również polubić